Ethical & compliant of unavailable pharmaceutical products

Healthcare professionals often face challenges in the treatment of many diseases where proper medicines are not available. Even some patients exceptionally reacted with available treatment. In such circumstances, doctors seek to access such medical intervention which may not get clinical approval due to unproven benefit. In such cases, making available of the products require ethical justifications for-and demands. Under special access programs (SAPs), patients get the opportunity for limited access to try such interventions that are not yet approved by standard regulatory processes.

Patients often faced difficulty to access specialized, unregistered, or commercially unavailable pharmaceutical products. In such conditions, certain agencies build pharma networks to support hospitals, healthcare professionals, pharmaceutical industry partners, and patients by providing ethical and compliant deliverance of such products. The pharma network has strong connections with biotechnology companies, pharmaceutical manufacturers, and suppliers across the world. An agreement is signed between Pharma Network and its client by following every ethical norm. The pharma network closely reviews the agreements which are periodically revised to update the regulatory compliance and make them up to date to allow the delivery of the products in different countries or regions. Thus, Pharma network service has committed to establishing a global association of pharmaceutical products and services.  The Pharma network takes the responsibility to supply the pharmaceutical products under specialist registered as well as unregistered items by following all the ethical and legislative compliance.

  • Specialist registered pharmaceutical products come under essential pharmaceutical products which are included emergency medicine, hematology, oncology, intensive care, analgesia/anesthesia, neurology, infectious diseases, rheumatology, endocrinology, dermatology, psychiatry, transplantation, and palliative care.
  • Unregistered medicines are commercially unavailable but  healthcare professional may seek such medicines to treat patients who require such treatment to increase their survival, or quality of living.  Such medicines are unregistered may due to they are in a clinical trial phase, off-label treatment, shortage supply, withdraw from the market.